Health News

Rx Prolongs Life...Without Pain
When cancer advances, the pain can be intense. A recently approved medicine may offer relief from both disease progression and pain.
More Life. Less Pain. Cancer Rx Delivers Both.
Zytiga ( abiraterone acetate) received expanded use approval to treat men with advanced prostate cancer last week. In addition to extending lives, a new study has found Zytiga also keeps men feeling better during their journey.
New Option For Late-Stage Prostate Cancer
Men with castration-resistant prostate cancer have another treatment option. The US Food and Drug Administration (FDA) has approved the expanded use of Zytiga (abiraterone acetate).
FDA Expands Zytiga’s use for Late-Stage Prostate Cancer
The US Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy.
Prostate Cancer – Separating Diagnosis From Treatment
September is National Prostate Cancer Awareness Month, and dailyRx  News wanted to learn about the state of the disease, its diagnosis and treatment. 
Expanding the Prostate Cancer Fight
Androgens are sometimes called the "male hormones."  They contribute to a man's sexual functions and are associated with secondary characteristics like chest and facial hair.
Prostate Cancer Drug Too Good To Test
Having a clinical trial canceled is a nightmare for researchers.  If the trial stops, researchers want it to be like this.
Rx Combo Fights Prostate Cancer Fatigue
Fatigue is a common and sometimes debillitating symptom for advanced-stage prostate cancer patients. And up until now, there have been few remedies. A prescription medication combination may soon be providing much-needed relief.
The Gift of Time
Life with advanced prostate cancer is measured in months, usually. The U.S. Food and Drug Administration (FDA) has recently approved a new medicine that offers men the gift of time.
FDA approves Zytiga for late-stage prostate cancer
The U.S. Food and Drug Administration (FDA) today approved Zytiga ( abiraterone acetate) in combination with prednisone (a steroid) to treat patients with late-stage (metastatic) castration-resistant prostate cancer who have received prior docetaxel (chemotherapy).